16.7.2014

Exit Strategy Checklist for Cashing in Your Startup – Legal Advisor’s Perspective

Exit strategy may not be the first thing on your mind when starting your startup. However, it should be. When you start your company, one of the key issues is to make a plan for how to get your money back at some stage in the future. And that interests your investors as well. How you finish is as essential to as how you start. You need to determine either your exit or your payoff, and you want to make sure that you have that option when the time comes.

From a legal advisor’s perspective, there are several options available as an exit strategy but, nowadays, the most common way is to sell your company. Moreover, a trend of early exits seems to attract many startups, and companies are often sold only 3—5 years after they are founded. Initial public offering (IPO) used to be a popular way to exit, but today companies find it much less tempting. Going public is such a massive project, requiring a proper infrastructure and a lot of effort and money, that most of the startups do not want to deal with it. Furthermore, as startups are typically exiting in such an early stage, most of them would not even fulfil the prerequisites required for an IPO. This is why we want to concentrate on acquisition – how to sell your startup company in a legally simple and easy way.

We have made a legal checklist for ‘how to sell a startup’. This checklist is useful when selling the whole stock or parts of it, or when just e.g. licensing the technology of your startup. Moreover, it is suitable not only when exiting, but also in every financing round. Keep in mind that getting capital investors involved in financing rounds may significantly increase the chances of a hefty exit of your startup. These are the reasons why this checklist is already worth taking out from day one of starting your business.

1. Keep your documentation in order, up-to-date and always in electronic form

It is crucial to have your documents available when you need them. Usually the need comes when you least expect it, and at the time of an acquisition or a financing round missing documentation can cause extra work, time and costs, unnecessary risks and other inconveniences.

Make sure that you conclude written agreements whenever possible and keep them properly recorded and safe. The same applies to statutory corporate documents. Also mind that your intellectual property rights are all properly protected, registered and duly transferred to the company, and that you have their documentation up to date.

The key is to keep legal risks low in the company all the time. In theory, the company should always withstand a check by a professional third party. In any case, there will be a due diligence (DD) phase in the event of selling your company or acquiring equity sponsors. Due diligence is an inspection of business made by a potential acquirer/equity sponsor. If the above-mentioned issues are maintained well, the company should be ready for a DD anytime.

2. Mind the confidential information of your company

During the DD phase, you need to be ready to answer a broad range of questions concerning your company. Still, be careful about how much and what kind of confidential information you want to introduce to potential acquirers at different stages of the DD phase.

A non-disclosure agreement (NDA) is essential before giving any confidential information to a potential acquirer. Bear in mind that you may be giving this information to your competitor and that they are not yet legally bound to buy your business at that stage. In particular, information relating to the most essential functions of business should typically not be given until the very end of the DD phase and not without sufficient deal security. However, the scope of an NDA depends on the nature of your company, and practicality should be kept in mind when protecting confidential information.

3. Use letters of intent to maximise strategic advantage

A letter of intent (LOI, also known as a term sheet) is a document outlining an agreement between the parties before the final sale and purchase agreement or the investment agreement is finalised. It basically determines how the deal is structured. The most common purposes of a LOI are to clarify the key points of transaction, declare officially that the parties are currently negotiating and provide safeguards in case the deal collapses. LOI is usually not entirely binding, but it often includes a confidentiality clause (substituting an NDA) and/or covenants providing exclusive rights to negotiate.

4. Develop effective strategies when negotiating the purchase price and other terms of the deal

Negotiation skills play a significant role after (or even simultaneously with) the DD phase until reaching a consensus on the sale and purchase price and other terms of the transaction such as liabilities, non-competition restrictions etc. It is important to structure and negotiate potential earn-out elements and critical risk allocation provisions, which might mean that you will need to accept responsibility for some risks a certain time after the transaction has been made.

The Sale and Purchase Agreement (SPA) represents the mutual acceptance on an offer, as a result of commercial and pricing negotiations. At this point, before signing an SPA, analyze the terms of an acquisition agreement and ensure that the agreement corresponds to what has been agreed.

Always be prepared to exit

This is a high-level checklist for the legal issues that need to be kept in mind when selling your startup company. We would like to highlight that planning and completing the exit properly may increase the entire value of your business outstandingly. However, an acquisition as a process is like a train – to reach its destination in time and painlessly, it requires a well-designed railway track. No matter how much you love your startup and how much it has become a lifestyle for you, you need to be prepared to exit, now and always. Design your exit well ahead and make it the most profitable part of all your business processes.

Tuomas Honkinen

Latest references

We are acting as legal adviser to Taaleri Plc on its acquisition of a 51 per cent ownership stake in Nordic Science Investments Oy (NSI), marking Taaleri’s expansion into deeptech-driven venture capital. Through the transaction, Taaleri broadens its private equity offering into early-stage venture capital funds as well as the commercialisation and scaling of research-driven innovations. NSI is a Finnish venture capital fund manager operating across the Nordic and Baltic regions, focusing on early-stage investments in research- and science-based technologies. Its portfolio companies develop, among other things, health technologies, life sciences, advanced materials and AI-driven solutions. In addition to providing growth capital, NSI supports spin-out companies with strategic guidance, access to networks and assistance in building teams during the early phases of business development. NSI’s first fund, the EUR 45 million NSI Nordic Science I Ky, was established in 2024 and has to date invested in 22 early-stage companies in Finland, Sweden and the Baltic countries. Taaleri is a specialist in investments, private asset management and non-life insurance, with a strong position in renewable energy, bioindustry and housing investments as well as credit risk insurance. Taaleri has EUR 2.7 billion of assets under management in its private equity funds, co-investments and single-asset vehicles, employs approximately 130 people and is listed on Nasdaq Helsinki. The founders of NSI will continue in their operational roles following the transaction. The completion of the transaction is subject to approval by the FIN-FSA.
Case published 13.4.2026
We advised Aurevia Oy, a portfolio company of French private equity sponsor Mérieux Equity Partners, in a strategic reorganisation that involved splitting Aurevia and its parent companies into two independent groups of companies and reorganisation of its existing debt-financing arrangements. Following the reorganisation, the newly formed Aurevia continues as a leading provider of Contract Research Organization (CRO) and Quality Assurance and Regulatory Affairs (QARA) services, while the newly formed Labquality focuses on delivering External Quality Assessment (EQA) services. Aurevia serves operators in the medical devices, in vitro diagnostics and pharmaceutical sectors. Labquality’s customers include clinical laboratories and social and healthcare organisations. The reorganisation positions Aurevia and Labquality to allocate investments more effectively, accelerate growth within their respective customer segments, and respond to evolving market and client needs. The transaction was implemented through multiple parallel demergers and required comprehensive legal and tax structuring across several jurisdictions. Our team supported Aurevia throughout the planning and implementation phases, covering corporate, tax, employment law, and regulatory matters, as well as the optimisation of each group’s financing structure.
Case published 7.4.2026
We are assisting CapMan Growth in its significant investment in Kuntokeskus Liikku, a Finnish gym chain known for its high-quality self-service facilities and excellent value for money. The investment will further strengthen Liikku’s position as a market leader and support the continued execution of its growth strategy. Liikku is one of Finland’s leading fitness chains, with more than 70 locations across the country serving nearly 90,000 members. The company’s concept is to offer high-quality self-service gyms at an exceptionally competitive price point which, combined with strong operational efficiency, provides a solid foundation for profitable growth. The company’s main shareholder is COR Group, a long-time partner of CapMan Growth, and a Finnish health and wellness conglomerate known for active ownership and long-term value creation. CapMan Growth is a leading Finnish growth investor that makes significant investments in entrepreneur-led growth companies with a turnover of €10–200 million. CapMan Growth is part of CapMan, which is a leading Nordic private equity investor engaged in active value creation work. CapMan has been listed on the Helsinki Stock Exchange since 2001.
Case published 27.2.2026
We acted as legal adviser to GEA Group AG in a directed share issue carried out by Solar Foods Oyj, in which GEA Finland Oy, a wholly owned subsidiary of GEA Group AG, acted as a cornerstone investor with an equity investment of EUR 8 million. Solar Foods raised a total of approximately EUR 25 million in gross proceeds from the share issue to accelerate the implementation of its new production facility Factory 02.  In connection with the share issue, GEA Liquid Technologies GmbH and Solar Foods signed an exclusivity agreement under which Solar Foods appoints GEA Liquid Technologies as its exclusive process equipment vendor for the supply, design, construction and delivery of the process equipment for the Factory 02. Additionally, the parties have undertaken to negotiate terms and conditions of a long-term strategic partnership in the area of gas fermentation and related technologies. GEA is one of the world’s largest systems suppliers for the food, beverage and pharmaceutical sectors. GEA’s portfolio includes machinery and plants as well as advanced process technology, components and comprehensive services. GEA is listed in the DAX and the STOXX® Europe 600 Index and is also among the companies comprising the DAX 50 ESG and MSCI Global Sustainability Indices. Solar Foods produces Solein®, a protein created using carbon dioxide and electricity. This innovative production method is independent of weather and climate conditions, eliminating the need for traditional agriculture. Founded in Finland in 2017, Solar Foods is listed on the Nasdaq First North Growth Market Finland.
Case published 26.1.2026